Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/25346165http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/25346165http://www.w3.org/2000/01/rdf-schema#comment"

Background

BRAF mutation has received a great deal of attention in neuro-oncology field, recently. This study aimed to investigate the incidence and the clinical significance of BRAF(V600E) in low-grade glial tumors.

Methods

An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.

Results

We found frequent BRAF(V600E) in DNTs (26/51, 51%), SEGAs (6/14, 42.9%), and PXAs (14/28, 50%). In DNTs, BRAF(V600E) was more commonly detected in tumors with extra-temporal location (68.2% vs. 37.9%; P = 0.032). The diagnostic subgroups of tuberous sclerosis complex were not correlated with BRAF(V600E) in patients with SEGA (P = 0.533). One PXA case revealed a unique duplication mutation (p.Thr599dup) of codon 599. All GMB-N cases did not carry BRAF mutation.

Conclusions

Our data indicate that BRAF(V600E) is a common genetic alteration in low-grade glial tumors with neuronal component or differentiation. High frequency of BRAF(V600E) in DNTs and SEGAs would be useful in the differential diagnosis, and also offers a potential specific treatment targeting BRAF(V600E) ."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.org/dc/terms/identifier"doi:10.1002/jso.23822"xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Lee D."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Cho Y.H."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Kang S.Y."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Yoon N."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Sung C.O."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/author"Suh Y.L."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/date"2015"xsd:gYear
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/name"J Surg Oncol"xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/pages"359-364"xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/title"BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas."xsd:string
http://purl.uniprot.org/citations/25346165http://purl.uniprot.org/core/volume"111"xsd:string
http://purl.uniprot.org/citations/25346165http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/25346165
http://purl.uniprot.org/citations/25346165http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/25346165
http://purl.uniprot.org/uniprot/#_P15056-mappedCitation-25346165http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/25346165
http://purl.uniprot.org/uniprot/P15056http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/25346165